We described the synthesis of a series of 1,2,3-triazolyl-4-oxoquinolines and evaluated their ability to inhibit oseltamivir (OST)-resistant influenza strains.
Introduction
Acute respiratory infections have a great impact on public health because they are a major cause of morbidity and mortality. Influenza virus, a negativesense-RNA orthomixovirus, is the most important etiologic agent of severe acute respiratory infections (SARI). Influenza virus causes both seasonal infections and pandemic outbreaks. Thus, neuraminidase inhibitors (NAIs) such as oseltamivir (OST), zanamivir, peramivir and laninamivir constitute the only licensed class of drugs available for clinical use against influenza. 4-Oxoquinolones and triazolic derivatives have been largely explored due to multiple biological properties. They have been proven to be active against viruses such as HIV, HSV, HCV and influenza. In this work, we synthesized new 4-oxoquinoline derivatives 1a-e and 2a-e in which this core was connected to a 1,2,3-triazole nucleus and investigated their ability to inhibit influenza virus replication and the NA activity of OST-resistant strains of influenza.
Results and Discussion
The azido-4-oxoquinolines 3a and 3b allowed us to study their application in the Huisgen "clickchemistry" reaction using copper sulfate and ascorbic acid as the catalysts and dimethylformamide as the solvent at 50 ºC. Compounds 1c and 1d were the most potent against the NA activity, reaching inhibitions equal to 89.0 and 94.8 %, respectively (OST=100 %). Compound 1d showed some advantages over OST in the inhibition of resistant strains of influenza. Although OST was more potent than compound 1d in the inhibition of wild-type (WT) strains, compound 1d IC 50 values suffered only marginal changes in the presence of resistance mutations to OST. Compound 1d was less cytotoxic than OST. Although OST' SI value is higher than the one observed for compound 2d, our molecule is still very safe to be used in vitro.
Conclusions
Oxoquinoline derivative 1d was the most potent compound within this series, inhibiting 94 % of WT influenza neuraminidase (NA) activity. Compound 1d inhibited influenza virus replication with an EC 50 of 0.2 µM with less cytotoxicity than OST, and also inhibited different OST-resistant NAs. These results suggest that 1,2,3-triazolyl-4-oxoquinolines represent promising lead molecules for further antiinfluenza drug design.
